Hunter Land

Hunter Land, PhD, MS, is a seasoned expert in scientific research and development strategy, with a career spanning two decades across more than 25 therapeutic areas. Over the past 14 years, he has emerged as a leading figure in cannabinoid research, notably as GW Pharmaceuticals’ first full-time U.S. R&D employee, where he played a pivotal role in advancing Epidiolex (CBD) program to FDA approval. He later led four FDA Phase II IND programs at BRC, a premier DEA Schedule I, FDA-compliant cannabinoid research organization. He now serves as CEO of Lupvindol Biosciences, leading two FDA CVM INAD programs for first in class therapies in veterinary medicine. His impact extends to intellectual property, with 15 patent applications as named inventor; over 20 peer-reviewed publications; more than 50 invited conference presentations; features in Forbes and Entrepreneur; and guest lectures at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy.